Jiangsu Skyray Instrument has been designated as a special treat and fined 3 million yuan. In recent years, there have been 10 other instances of illegal operation in production and management. | Quick read of the announcement.

① Jiangsu Skyray Instrument was fined 3 million yuan by the Securities Regulatory Commission, and several executives including chairman Liu Zhaogui were also penalized; ② The company's stocks will be subject to other risk warnings by the Shenzhen Stock Exchange, changed to "ST Jiangsu Skyray"; ③ In recent years, the company has faced up to 10 cases of violations related to environmental protection, safety regulations, and other operational misconduct.

cls.cnDec 8 20:46

Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.

①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.

cls.cnDec 2 11:01

Autobio diagnostics: The molecular sector is experiencing rapid growth, and disputes with the secondary subsidiary may be resolved soon | Direct coverage of the earnings conference.

① The secretary of the board of directors of autobio diagnostics stated at the earnings conference that the significant increase in research and development expenses led to a decline in the net income attributable to the parent company in Q3; ② The chairman of autobio diagnostics, Miao Yongjun, told investors that the molecular sector is expected to maintain a high growth rate, while the microbiology sector will have a steady growth of 15%-20% each year.

cls.cnNov 25 19:44

Huawei's global embodied asia vets industry innovation center has been launched, institutions suggest paying attention to the Huawei siasun robot&automation ecosystem.

On November 15, a conference will be held in Qianhai, Shenzhen, and Bao'an to release innovative achievements in ai applications. At that time, Huawei (Shenzhen) global embodied intelligence industry innovation center will start its operation and hold a preferred partner signing ceremony. The open-source securities machinery team believes that Huawei possesses capabilities similar to Tesla, and has already made early investments in the siasun robot&automation field, initially establishing an ecosystem. Currently, it has advantages in global ai and large model software.

cls.cnNov 15 07:53

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

① During the earnings conference, fosun pharma stated that the company's performance improved year-on-year in Q3 due to factors such as the continuous increase in innovative drug volume. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the rapid上市 and sales of injectable type A botulinum toxin within china. ③ The privatization process of henlius and the accessibility of CAR-T products are also receiving significant attention.

cls.cnNov 13 21:52

yabao pharmaceutical group saw a year-on-year increase in revenue for two children's medications. Revenue for the injection of Benatuostin hydrochloride has not yet stopped declining. | Directly focusing on the earnings conference

At the earnings conference, yabao pharmaceutical group stated that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary of the board also mentioned that while the revenue of Tenatoprazole Hydrochloride Injection decreased, sales volume increased, and predicted that the 'income decline in this category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the progress of the company's R&D pipeline, share buybacks, and other situations.

cls.cnNov 12 12:48